Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
Scale Biosciences and Revvity's BioLegend (NYSE: RVTY) have launched the TotalSeq Phenocyte solution, a groundbreaking single-cell protein profiling technology. This innovation combines Scale Bio's Quantum Barcoding technology with BioLegend's TotalSeq antibody conjugates to enable more efficient identification and characterization of rare cell subtypes in immunology and oncology research.
The solution offers advantages over traditional methods like mass cytometry and flow cytometry by eliminating complex panel optimization and sophisticated instrumentation requirements, making it more accessible and scalable. It builds upon BioLegend's TotalSeq-A antibody panels and supports biomarker discovery without requiring dedicated instrumentation.
Scale Biosciences e BioLegend di Revvity (NYSE: RVTY) hanno lanciato la soluzione TotalSeq Phenocyte, una tecnologia innovativa per il profilo proteico a singola cellula. Questa innovazione combina la tecnologia Quantum Barcoding di Scale Bio con i coniugati degli anticorpi TotalSeq di BioLegend per consentire un'identificazione e una caratterizzazione più efficienti dei sottotipi cellulari rari nella ricerca in immunologia e oncologia.
La soluzione offre vantaggi rispetto ai metodi tradizionali come la citometria di massa e la citometria a flusso, eliminando l'ottimizzazione complessa dei pannelli e le esigenze di strumentazione sofisticata, rendendola più accessibile e scalabile. Si basa sui pannelli di anticorpi TotalSeq-A di BioLegend e supporta la scoperta di biomarcatori senza la necessità di strumentazione dedicata.
Scale Biosciences y BioLegend de Revvity (NYSE: RVTY) han lanzado la solución TotalSeq Phenocyte, una tecnología innovadora de perfilado de proteínas a célula única. Esta innovación combina la tecnología Quantum Barcoding de Scale Bio con los conjugados de anticuerpos TotalSeq de BioLegend para permitir una identificación y caracterización más eficientes de subtipos celulares raros en la investigación en inmunología y oncología.
La solución ofrece ventajas sobre métodos tradicionales como la citometría de masas y la citometría de flujo al eliminar la optimización compleja de paneles y los requisitos de instrumentación sofisticada, haciéndola más accesible y escalable. Se basa en los paneles de anticuerpos TotalSeq-A de BioLegend y apoya el descubrimiento de biomarcadores sin necesidad de instrumentación dedicada.
Scale Biosciences와 Revvity의 BioLegend (NYSE: RVTY)는 혁신적인 단일 세포 단백질 프로파일링 기술인 TotalSeq Phenocyte 솔루션을 출시했습니다. 이 혁신은 Scale Bio의 Quantum Barcoding 기술과 BioLegend의 TotalSeq 항체 접합체를 결합하여 면역학 및 종양학 연구에서 희귀 세포 아형을 보다 효율적으로 식별하고 특성화할 수 있게 합니다.
이 솔루션은 복잡한 패널 최적화 및 정교한 기기 요구 사항을 제거하여 전통적인 방법인 질량 세포 측정법 및 흐름 세포 측정법보다 장점을 제공합니다. 따라서 더 접근 가능하고 확장 가능합니다. BioLegend의 TotalSeq-A 항체 패널을 기반으로 하며, 전용 기기 없이 바이오마커 발견을 지원합니다.
Scale Biosciences et BioLegend de Revvity (NYSE: RVTY) ont lancé la solution TotalSeq Phenocyte, une technologie révolutionnaire de profilage protéique à cellule unique. Cette innovation combine la technologie Quantum Barcoding de Scale Bio avec les conjugués d’anticorps TotalSeq de BioLegend pour permettre une identification et une caractérisation plus efficaces des sous-types cellulaires rares dans la recherche en immunologie et en oncologie.
La solution offre des avantages par rapport aux méthodes traditionnelles telles que la cytométrie de masse et la cytométrie en flux, en éliminant l'optimisation complexe des panels et les exigences instrumentales sophistiquées, la rendant ainsi plus accessible et évolutive. Elle s'appuie sur les panneaux d'anticorps TotalSeq-A de BioLegend et soutient la découverte de biomarqueurs sans nécessiter d'instrumentation dédiée.
Scale Biosciences und BioLegend von Revvity (NYSE: RVTY) haben die TotalSeq Phenocyte-Lösung eingeführt, eine bahnbrechende Technologie zur Einzelzellen-Proteinprofilierung. Diese Innovation kombiniert die Quantum Barcoding-Technologie von Scale Bio mit den TotalSeq-Antikörperkonjugaten von BioLegend, um eine effizientere Identifizierung und Charakterisierung seltener Zellsubtypen in der Immunologie- und Onkologie-Forschung zu ermöglichen.
Die Lösung bietet Vorteile gegenüber traditionellen Methoden wie der Massenspektrometrie und der Durchflusszytometrie, indem sie komplexe Paneloptimierungen und anspruchsvolle Instrumentierungsanforderungen eliminiert, wodurch sie zugänglicher und skalierbarer wird. Sie baut auf BioLegends TotalSeq-A-Antikörperpanels auf und unterstützt die Entdeckung von Biomarkern, ohne eine spezielle Instrumentierung zu erfordern.
- First-to-market innovative solution for high-parameter protein profiling
- Enables more efficient identification of rare cell subtypes
- Offers better scalability across multiple samples compared to traditional methods
- More cost-effective than existing high-parameter cytometry tools
- to research use only, not approved for diagnostic procedures
Insights
The launch of TotalSeq Phenocyte represents a significant advancement in single-cell analysis technology, but its immediate financial impact on Revvity appears While innovative, this research-use-only product enters a competitive market dominated by established players in flow cytometry and mass spectrometry. Key advantages include:
- Cost-effective scaling compared to traditional methods
- Simplified workflow without requiring specialized equipment
- Enhanced ability to detect rare cell types
The TotalSeq Phenocyte solution supports robust study of cellular heterogeneity and rare cell types in complex samples at a single cell level
While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples.
“By leveraging TotalSeq antibodies and a single-cell genomics-based workflow, this product supports the identification of low frequency events within a cell population. This allows for the study of many more markers than could be observed in a single experiment using other cell analysis technologies to study cell populations,” said Craig Monell, senior vice president, reagents, Revvity. “Even with capital-intensive high parameter cytometry tools, we are not able to scale the same level of detection of rare cell types as we can with the TotalSeq Phenocyte solution.”
“Scale Bio is focused on leveraging the power of our new Quantum Barcoding technology to enable researchers to dramatically scale up their research by being able to explore more cells, more samples, across more modalities, with simple workflows and an accessible price point. This is just the first of many Scale Bio offerings that will leverage our powerful single cell omics platform to enable more single cell omics insights,” said Giovanna Prout, president and CEO of Scale Bio. “The launch of the TotalSeq Phenocyte solution, made available through our collaboration with BioLegend, is the first time we’ve collaborated with another company to bring together disparate technologies into a single solution that supports our customers in upleveling their immunology and oncology research.”
The new offering builds upon BioLegend’s well validated TotalSeq-ATM antibody panels and Scale Bio’s Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation.
“We are proud to collaborate with Scale Bio to bring our customers this novel, high parameter, protein-focused workflow to accelerate immunology and oncology research,” said Gene Lay, senior vice president, life sciences at Revvity. “This offering provides a cost-effective, high throughput solution that supports the study of rare cell subtypes, the acceleration of biomarker discovery, and the characterization of precious samples.”
The TotalSeq Phenocyte solution is now shipping.
For research use only. Not for use in diagnostic procedures.
About Scale Biosciences
At Scale Bio, we are committed to accelerating scientific breakthroughs by providing innovative single cell omics solutions that redefine accessibility, flexibility, and scalability, empowering researchers to unlock the full potential of single cell omics. Leveraging our core massively parallelized single cell barcoding technology, we offer a range of advanced workflow solutions that maximize insights delivered with every experiment and sample type, allowing scientists to generate more data, analyze more samples, and explore more omics, cost efficiently and with unprecedented ease. Founded by scientists and technologists with experience across a range of multiomics disciplines, Scale Bio has attracted financing from leading life sciences tools investors including ARCH Venture Partners, BNG01 and Tao Capital. Scale Bio is headquartered in
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119715767/en/
For Scale Bio
For Media
Gwen Gordon
gwen@gwengordonpr.com
For General Inquiries
info@scale.bio
Revvity Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Revvity Investor Relations
Steve Willoughby
steve.willoughby@revvity.com
Source: Scale Biosciences
FAQ
What is the TotalSeq Phenocyte solution launched by Revvity (RVTY)?
What advantages does Revvity's (RVTY) new TotalSeq Phenocyte solution offer?
Is Revvity's (RVTY) TotalSeq Phenocyte solution approved for diagnostic use?
